Kenvue Inc. Common Stock vs T1 Energy Inc. Common Stock — how do they compare? Kenvue Inc. Common Stock trades at $18.15 (market cap $34.11B), while T1 Energy Inc. Common Stock trades at $2.8 (market cap $946.42M). The key difference: Kenvue Inc. Common Stock is far larger — about 36× T1 Energy Inc. Common Stock's market cap, and Kenvue Inc. Common Stock pays a 4.73% dividend while T1 Energy Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kenvue Inc. Common Stock for 1 Days and T1 Energy Inc. Common Stock for 0 Days on average.
| KVUE | TE | |
|---|---|---|
Market Cap | $34.11B | $946.42M |
Volume | 27,388,811 | 12,898,774 |
Sector | Consumer Staples | Industrials |
52-Week High | $19.83 | $12.04 |
52-Week Low | $14.11 | $2.72 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $41.62B | $1.72B |
Dividend Yield | 4.73% | — |
Signals from Pluang's Aura AI — not financial advice
Kenvue (KVUE) trades at $17.76, down 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $15.12B in 2025, with a net income margin of 10.76% and a P/E ratio of 20.89. Recent news highlights conditional EU approval for Kimberly-Clark's $40B acquisition of Kenvue, potentially impacting future operations and shareholder returns.
The outlook is mixed, with strong profitability and consistent dividend payments offering stability, but the pending acquisition introduces uncertainty. Risks include integration challenges and market volatility. Analyst consensus is a Hold with a $19.50 price target, suggesting limited near-term upside from current levels.
T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.
The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.
Read more on TE →